Literature DB >> 23812389

Eukaryotic elongation factor 2 kinase regulates the development of hypertension through oxidative stress-dependent vascular inflammation.

Tatsuya Usui1, Muneyoshi Okada, Yukio Hara, Hideyuki Yamawaki.   

Abstract

Eukaryotic elongation factor 2 kinase (eEF2K) is a Ca2+/calmodulin-dependent protein kinase. We recently demonstrated that eEF2K protein increases in mesenteric artery from spontaneously hypertensive rats (SHR). Pathogenesis of hypertension is regulated in part by vascular inflammation. We tested the hypothesis whether eEF2K mediates vascular inflammatory responses and development of hypertension. In vascular endothelial cells, small interfering RNA (siRNA) against eEF2K inhibited induction of VCAM-1 and endothelial-selectin as well as monocyte adhesion by TNF-α (10 ng/ml). eEF2K siRNA inhibited phosphorylation of JNK and NF-κB p65 as well as reactive oxygen species (ROS) production by TNF-α. In vascular smooth muscle cells, eEF2K siRNA also inhibited VCAM-1 induction and phosphorylation of JNK and NF-κB by TNF-α. In vivo, increased blood pressure in SHR and ROS production, induction of inflammatory molecules, and hypertrophy in SHR superior mesenteric artery were reduced by an eEF2K inhibitor NH125 (500 μg·kg(-1)·day(-1)). In SHR superior mesenteric artery, impairment of ACh-induced relaxation was normalized by NH125. The present results for the first time demonstrate that eEF2K mediates TNF-α-induced vascular inflammation via ROS-dependent mechanism, which is at least partly responsible for the development of hypertension in SHR.

Entities:  

Keywords:  hypertension; inflammation; reactive oxygen species; signal transduction; vasoconstriction

Mesh:

Substances:

Year:  2013        PMID: 23812389      PMCID: PMC4073962          DOI: 10.1152/ajpheart.00373.2013

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  43 in total

Review 1.  Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway.

Authors:  Jaroslaw Jozwiak; Sergiusz Jozwiak; Tomasz Grzela; Maciej Lazarczyk
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

2.  Calcium/calmodulin-dependent protein kinase II-delta isoform regulation of vascular smooth muscle cell proliferation.

Authors:  Suzanne J House; Roman G Ginnan; Shayn E Armstrong; Harold A Singer
Journal:  Am J Physiol Cell Physiol       Date:  2007-01-31       Impact factor: 4.249

3.  Methylglyoxal accumulation in arterial walls causes vascular contractile dysfunction in spontaneously hypertensive rats.

Authors:  Masashi Mukohda; Muneyoshi Okada; Yukio Hara; Hideyuki Yamawaki
Journal:  J Pharmacol Sci       Date:  2012-08-23       Impact factor: 3.337

4.  Plasma levels of soluble cellular adhesion molecules in patients with arterial hypertension. Correlations with plasma endothelin-1.

Authors:  J T. Parissis; K F. Venetsanou; D G. Mentzikof; M V. Kalantzi; M V. Georgopoulou; N Chrisopoulos; S M. Karas
Journal:  Eur J Intern Med       Date:  2001-07       Impact factor: 4.487

5.  Mechanisms underlying impairment of endothelium-dependent relaxation by fetal bovine serum in organ-cultured rat mesenteric artery.

Authors:  Tomoka Morita; Muneyoshi Okada; Yukio Hara; Hideyuki Yamawaki
Journal:  Eur J Pharmacol       Date:  2011-08-10       Impact factor: 4.432

Review 6.  Redox signaling in hypertension.

Authors:  Tamara M Paravicini; Rhian M Touyz
Journal:  Cardiovasc Res       Date:  2006-05-09       Impact factor: 10.787

7.  Elongation factor-2 kinase: its role in protein synthesis and autophagy.

Authors:  William N Hait; Hao Wu; Shenkan Jin; Jin-Ming Yang
Journal:  Autophagy       Date:  2006-10-03       Impact factor: 16.016

8.  Role of calmodulin-dependent phosphorylation of elongation factor 2 in the proliferation of rat glial cells.

Authors:  D M Bagaglio; W N Hait
Journal:  Cell Growth Differ       Date:  1994-12

9.  Death-associated protein kinase 3 mediates vascular inflammation and development of hypertension in spontaneously hypertensive rats.

Authors:  Tatsuya Usui; Muneyoshi Okada; Yukio Hara; Hideyuki Yamawaki
Journal:  Hypertension       Date:  2012-08-06       Impact factor: 10.190

10.  Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines.

Authors:  Sonia Arora; Jin-Ming Yang; Terri Goss Kinzy; Ryutaro Utsumi; Tadashi Okamoto; Takashi Kitayama; Pedro A Ortiz; William N Hait
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

View more
  10 in total

1.  Structural Basis for the Recognition of Eukaryotic Elongation Factor 2 Kinase by Calmodulin.

Authors:  Kwangwoon Lee; Sébastien Alphonse; Andrea Piserchio; Clint D J Tavares; David H Giles; Rebecca M Wellmann; Kevin N Dalby; Ranajeet Ghose
Journal:  Structure       Date:  2016-08-04       Impact factor: 5.006

2.  Solution Structure of the Carboxy-Terminal Tandem Repeat Domain of Eukaryotic Elongation Factor 2 Kinase and Its Role in Substrate Recognition.

Authors:  Andrea Piserchio; Nathan Will; David H Giles; Fatlum Hajredini; Kevin N Dalby; Ranajeet Ghose
Journal:  J Mol Biol       Date:  2019-05-18       Impact factor: 5.469

3.  Multiple activation mechanisms of serotonin-mediated contraction in the carotid arteries obtained from spontaneously hypertensive rats.

Authors:  Shun Watanabe; Takayuki Matsumoto; Makoto Ando; Tsuyuki Adachi; Shota Kobayashi; Maika Iguchi; Miki Takeuchi; Kumiko Taguchi; Tsuneo Kobayashi
Journal:  Pflugers Arch       Date:  2016-05-12       Impact factor: 3.657

Review 4.  Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.

Authors:  Rui Liu; Christopher G Proud
Journal:  Acta Pharmacol Sin       Date:  2016-01-25       Impact factor: 6.150

5.  The role of calcium in the interaction between calmodulin and a minimal functional construct of eukaryotic elongation factor 2 kinase.

Authors:  Kwangwoon Lee; Eric A Kumar; Kevin N Dalby; Ranajeet Ghose
Journal:  Protein Sci       Date:  2019-12       Impact factor: 6.725

6.  Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth In Vivo.

Authors:  Ferah Comert Onder; Nermin Kahraman; Esen Bellur Atici; Ali Cagir; Hakan Kandemir; Gizem Tatar; Tugba Taskin Tok; Goknur Kara; Bekir Karliga; Serdar Durdagi; Mehmet Ay; Bulent Ozpolat
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-30

7.  Impairing eukaryotic elongation factor 2 kinase activity decreases atherosclerotic plaque formation.

Authors:  Peng Zhang; Maziar Riazy; Matthew Gold; Shu-Huei Tsai; Kelly McNagny; Christopher Proud; Vincent Duronio
Journal:  Can J Cardiol       Date:  2014-09-28       Impact factor: 5.223

8.  Eukaryotic elongation factor 2 kinase inhibitor, A484954 potentiates β-adrenergic receptor agonist-induced acute decrease in diastolic blood pressure in rats.

Authors:  Tomoko Kodama; Muneyoshi Okada; Hideyuki Yamawaki
Journal:  J Vet Med Sci       Date:  2019-09-05       Impact factor: 1.267

9.  Age-dependent increase in activity of eukaryotic elongation factor 2 kinase in mesenteric arteries from spontaneously hypertensive rats.

Authors:  Tomoko Kodama; Kosuke Otani; Muneyoshi Okada; Hideyuki Yamawaki
Journal:  J Vet Med Sci       Date:  2020-11-16       Impact factor: 1.267

10.  Identification of Key Pathways and Genes in Obesity Using Bioinformatics Analysis and Molecular Docking Studies.

Authors:  Harish Joshi; Basavaraj Vastrad; Nidhi Joshi; Chanabasayya Vastrad; Anandkumar Tengli; Iranna Kotturshetti
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-24       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.